Concepedia

Imran Khan

IK

Statistics

Publications

22

Citations

3.6K

H-Index

19

Active since

2004

Affiliations

Janssen (United States)(Current)

Emory University

Levine Cancer Institute

Carolinas Healthcare System

Amsterdam UMC Location Vrije Universiteit Amsterdam

Imran Khan is an author at Janssen (United States) specializing in multiple myeloma, daratumumab therapy, and immunotherapy.

ORCID

Publications per year

2004–2018

22

Publications

22

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

Henk M. Lokhorst, Torben Plesner, Jacob P. Laubach et al. · New England Journal of Medicine · 2015 · 1.1K citations · Full text

, , +17

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Sagar Lonial, Brendan M. Weiss, Saad Z. Usmani et al. · The Lancet · 2016 · 850 citations

, , +14

Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma

Saad Z. Usmani, Brendan M. Weiss, Torben Plesner et al. · Blood · 2016 · 404 citations · Full text

, , +14

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

Tineke Casneuf, Xu Steven Xu, Homer Adams et al. · Blood Advances · 2017 · 224 citations · Full text

, , +16

Analysis and evaluation of a biomedical polycarbonate urethane tested in an in vitro study and an ovine arthroplasty model. Part I: materials selection and evaluation

Imran Khan, Nigel Smith, Eric Jones et al. · Biomaterials · 2004 · 181 citations

, , +14

1–5 of 22